Literature DB >> 25402762

A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.

Semra Demir1, Muge Olgac, Derya Unal, Asli Gelincik, Bahauddin Colakoglu, Suna Buyukozturk.   

Abstract

Orally administered iron salts (OAS) are widely used in the management of iron deficiency anemia and hypersensitivity reactions to OAS are not common. If an offending drug is the sole option or is significantly more effective than its alternatives, it can be readministered by desensitization. The oral desensitization protocols for iron published so far concern either desensitization that was completed only over a long period or did not attain the recommended therapeutic dose. We aimed to develop a more effective protocol. We report here on 2 patients who experienced hypersensitivity reactions to OAS. After confirming the diagnosis, both patients were desensitized to oral ferrous (II) glycine sulfate complex according to a 2-day desensitization protocol. A commercial suspension of oral ferrous glycine sulfate, which contains 4 mg of elemental iron in 1 ml, was preferred. We started with a dose as low as 0.1 ml from a 1/100 dilution (0.004 mg elemental iron) of the original suspension and reached the maximum effective dose in 2 days. Both patients were successfully desensitized and they went on to complete the 6-month iron treatment without any adverse effects. Although hypersensitvity reactions to iron are not common, there is no alternative for iron administration. Therefore, desensitization has to be the choice. This easy desensitization protocol seems to be a promising option.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25402762     DOI: 10.1159/000368407

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  1 in total

1.  A successful protocol for desensitization to iron salts.

Authors:  Kadriye Terzioglu; Kürşat Epöztürk
Journal:  Indian J Pharmacol       Date:  2021 Jul-Aug       Impact factor: 1.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.